CAS 356559-20-1|SB525334

Introduction：Basic information about CAS 356559-20-1|SB525334, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. SB525334 BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Customs
6. Articles5
7. Synonyms

Common Name	SB525334
CAS Number	356559-20-1	Molecular Weight	343.425
Density	1.2±0.1 g/cm3	Boiling Point	540.5±45.0 °C at 760 mmHg
Molecular Formula	C₂₁H₂₁N₅	Melting Point	159 °C
MSDS	ChineseUSA	Flash Point	238.6±21.7 °C
Symbol	GHS06	Signal Word	Danger

Names

Name	6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline
Synonym	More Synonyms

SB525334 BiologicalActivity

Description	SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM.
Related Catalog	Signaling Pathways >>TGF-beta/Smad >>TGF-β ReceptorResearch Areas >>Cancer
References	[1]. Grygielko ET, et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther, 2005, 313(3), 943-951. [2]. Thomas M, et al. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol, 2009, 174(2), 380-389. [3]. Laping NJ, et al. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res, 2007, 13(10), 3087-3899.

Description

SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM.

Related Catalog

Signaling Pathways >>TGF-beta/Smad >>TGF-β ReceptorResearch Areas >>Cancer

References

[1]. Grygielko ET, et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther, 2005, 313(3), 943-951.

[2]. Thomas M, et al. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol, 2009, 174(2), 380-389.

[3]. Laping NJ, et al. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res, 2007, 13(10), 3087-3899.

Chemical & Physical Properties

Density	1.2±0.1 g/cm3
Boiling Point	540.5±45.0 °C at 760 mmHg
Melting Point	159 °C
Molecular Formula	C₂₁H₂₁N₅
Molecular Weight	343.425
Flash Point	238.6±21.7 °C
Exact Mass	343.179688
PSA	67.35000
LogP	4.05
Appearance of Characters	yellow
Vapour Pressure	0.0±1.4 mmHg at 25°C
Index of Refraction	1.636
InChIKey	DKPQHFZUICCZHF-UHFFFAOYSA-N
SMILES	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3nccnc3c2)n1
Storage condition	2-8°C
Water Solubility	DMSO: ≥20mg/mL

Safety Information

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H301-H315-H319-H335-H413
Precautionary Statements	P261-P301 + P310-P305 + P351 + P338
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Faceshields;Gloves
Hazard Codes	Xn
Risk Phrases	22-36/37/38
Safety Phrases	26
RIDADR	UN 2811 6.1/PG 3
Hazard Class	6.1
HS Code	2934999090

Customs

HS Code	2934999090
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles5

Mesenchymal activin-A overcomes defective human trisomy 21 trophoblast fusion.

Endocrinology 152 , 5017-28, (2011)

Placental development is markedly abnormal in trisomy 21 (T21) pregnancies. We hypothesized that abnormal paracrine cross talk between the fetal mesenchymal core and the trophoblast might be involved ...

Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.

J. Pharmacol. Exp. Ther. 313 , 943-951, (2005)

SB-525334 (6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline) has been characterized as a potent and selective inhibitor of the transforming growth factor-beta1 (TGF-beta1) recep...

Activin-Like Kinase 5 (ALK5) Mediates Abnormal Proliferation of Vascular Smooth Muscle Cells from Patients with Familial Pulmonary Arterial Hypertension and Is Involved in the Progression of Experimental Pulmonary Arterial Hypertension Induced by Monocrotaline

Am. J. Pathol. 174(2) , 380-9, (2009)

Mutations in the gene for the transforming growth factor (TGF)-β superfamily receptor, bone morphogenetic protein receptor II, underlie heritable forms of pulmonary arterial hypertension (PAH). Aberra...

Synonyms

6-[2-tert-Butyl-4-(6-methylpyridin-2-yl)-1H-imidazol-5-yl]quinoxaline

6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline

SB 525334

Quinoxaline, 6-[2-(1,1-dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]-

6-[2-(2-Methyl-2-propanyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline

6-(2-tert-butyl-4-(6-methylpyridin-2-yl)-1H-imidazol-5-yl)quinoxaline

S1476_Selleck

SB525334

6-(2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline

6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline

Recommended......